Kigabeq is a medicine for treating epilepsy in children between 1 month and 7 years of age. It is used in the following ways: - on its own to treat infantile spasms (West syndrome), a rare epilepsy disorder that starts at a very young age, usually in the first few months of life; - together with other medicines to treat partial epilepsy (seizures affecting one part of the brain), including when the seizures spread to other parts of the brain and become more generalised. Kigabeq is only used in partial epilepsy when patients have already tried all other appropriate treatments or cannot use them because of side effects. Kigabeq contains the active substance vigabatrin and is a ‘hybrid medicine’. This means that it is similar to a ‘reference medicine’ containing the same active substance, but Kigabeq is available in a different form and strengths. The reference medicine for Kigabeq is Sabril (500 mg granules).
Therapeutic Indication
### Therapeutic indication Kigabeq is indicated in infants and children from 1 month to less than 7 years of age for: - Treatment in monotherapy of infantile spasms (West's syndrome). - Treatment in combination with other antiepileptic medicinal products for patients with resistant partial epilepsy (focal onset seizures) with or without secondary generalisation, that is where all other appropriate medicinal product combinations have proved inadequate or have not been tolerated.
Therapeutic Area (MeSH)
ATC Code
N03AG04
ATC Item
vigabatrin
Pharmacotherapeutic Group
Antiepileptics
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| vigabatrin | N/A | 氨己烯酸 |
EMA Name
Kigabeq
Medicine Name
Kigabeq
Aliases
N/ANo risk management plan link.
